Financial Performance & Outlook - Q2 2025 revenues reached $78 million, with Thermal Barrier revenues accounting for $55.2 million, a 13% QoQ increase[9] - Energy Industrial maintained gross margins of 35%+ on revenues of $22.8 million in Q2 2025[9] - Adjusted EBITDA for Q2 2025 was $9.7 million, reflecting ~2X QoQ growth on similar revenues[9] - The company anticipates a ~2X improvement in Adjusted EBITDA on similar revenue in H2 2025[8] - H2 2025 revenue is projected to be in the range of $140 million to $160 million, with Adjusted EBITDA between $20 million and $30 million[7,8,12] - Full year 2025 Adjusted EBITDA is projected to be $35 million to $45 million[12] Cost Management & Capital Expenditure - Fixed cost reductions are expected to drive improved financial performance in H2 2025[6] - CAPEX spend in Q2 2025 was reduced by 50% YoY due to demobilizing Plant II and EV Thermal Barrier Equipment[9] - CAPEX for H2 2025 is projected at $10 million, leading to a full year CAPEX of $25 million[12] Electric Vehicle (EV) Market - General Motors (GM) is gaining EV market share in the US[21] - GM's North American EV production forecast for 2025 is approximately 241,000 units[24] - The Equinox model is expected to represent ~24% of GM's total EV volume in 2026[26]

"SAFE HARBOR" FORWARD-LOOKING STATEMENT | DEFINED TERMS Part of Liberty Latin America LIBERTY LATIN AMERICA Q2 & H1 2025 INVESTOR CALL August 7, 2025 AGENDA EXECUTIVE SUMMARY 01 | 02 | FINANCIAL RESULTS 03 | APPENDIX FORWARD-LOOKING STATEMENTS & DISCLAIMER This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategies, priorities and objectives, financial and operational performance, growth expec ...

Financial Performance & Growth - N-able's Annual Recurring Revenue (ARR) reached $514 million [9] - The company achieved an ARR growth rate of 14% [9] - N-able's Net Retention Rate (TTM) is 102% [9] - The Non-GAAP Adjusted EBITDA Margin (TTM) is 32% [9] - The Non-GAAP Gross Margin (TTM) is 82% [9] Market Opportunity & Strategy - The Small and Mid-market Business (SMB & Mid-market) IT Total Addressable Market (TAM) is estimated at $2.1 trillion in 2025 [13] - N-able estimates a cross-sell opportunity of over $2.5 billion across its product lines [51] - N-able projects an Average Revenue Per Customer TTM of $194000 in Q2 2025 [61] Future Outlook - N-able anticipates Q3 2025 ARR to be between $525 million and $530 million, representing a year-over-year growth of 9-10% [63] - The company forecasts Q3 2025 revenue to be between $127 million and $128 million, a year-over-year increase of 9-10% [63] - N-able expects Q3 2025 Adjusted EBITDA margin to be 28%-29%, translating to $36 million - $37 million [63] - N-able projects FY'25 revenue to be between $500 million and $503 million, a year-over-year increase of 7-8% [63]

Financial Performance - Q2 2025 revenue reached $345.3 million, an 11% year-over-year increase[9] - Q2 2025 Center Margin was $108.4 million, representing 31.4% of revenue[9] - Q2 2025 Adjusted EBITDA was $34.0 million, or 9.8% of revenue[9] - The company ended Q2 2025 with a cash position of $188.9 million[9] - Full year 2025 revenue guidance is reaffirmed at $1.40 billion - $1.44 billion[19] - Full year 2025 Adjusted EBITDA guidance is raised to $140 million - $150 million[19] Operational Metrics - Total clinicians reached 7,708, an 11% year-over-year growth, with 173 net clinician additions in Q2[9, 8] - Q2 2025 visit volumes increased by 12% year-over-year to 2.2 million[9] - The company operates over 550 centers in 33 states[8] Balance Sheet and Capital Allocation - Cash and cash equivalents totaled $189 million[17] - Net long-term debt is $273 million[17]

INVESTOR UPDATE August 7, 2025 TODAY'S PRESENTERS Steve Altemus CO-FOUNDER, PRESIDENT & CHIEF EXECUTIVE OFFICER Pete McGrath CHIEF FINANCIAL OFFICER Disclaimer & Forward Looking Statement This presentation (and oral statements made regarding the subjects of this presentation) includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements that do not relate to matters of historical fact should be considered forward looking. These ...

Presentation Q2 2025 Results Presentation August 7, 2025 Company Disclaimer IMPORTANT NOTICE This presentation includes forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, industry dynamics, business strategy and plans and our objectives for future operations, are forward-looking statements. These statements represent our opinions, expectations, beliefs, in ...

Financial Performance - Fire Safety revenue increased by 22% to $120284 thousand in Q2 2025 and 27% to $157447 thousand YTD 2025[15] - Fire Safety adjusted EBITDA increased by 40% to $77659 thousand in Q2 2025 and 58% to $87744 thousand YTD 2025, with adjusted EBITDA margin of 65% in Q2 2025 and 56% YTD 2025[15] - Specialty Products revenue increased by 47% to $42355 thousand in Q2 2025 and 23% to $77222 thousand YTD 2025[15] - Specialty Products adjusted EBITDA increased by 48% to $13679 thousand in Q2 2025, but remained flat at $21677 thousand YTD 2025, with adjusted EBITDA margin of 32% in Q2 2025 and 28% YTD 2025[15] - Consolidated revenue increased by 28% to $162639 thousand in Q2 2025 and 26% to $234669 thousand YTD 2025[15] - Consolidated adjusted EBITDA increased by 41% to $91338 thousand in Q2 2025 and 42% to $109421 thousand YTD 2025, with adjusted EBITDA margin of 56% in Q2 2025 and 47% YTD 2025[15] Capital Structure and Allocation - Net debt to LTM adjusted EBITDA is 17x, with LTM adjusted EBITDA of $312671 thousand[18, 22, 33] - The company has $1407 million in cash and cash equivalents as of Q2 2025[22] - Capital expenditures for Q2 2025 were $97 million, with $200 million allocated to M&A and $322 million to share buybacks[18] Long-Term Assumptions - Annual interest expense is projected to be approximately $40 million[16] - Annual tax-deductible depreciation and amortization are projected to be approximately $20-25 million[16] - The cash tax rate is estimated to be around 20-25%[16]

Q2 2025 Financial Performance - Revenue reached $973 million[10], exceeding guidance due to increased demand in Semiconductor and Electronic & Packaging markets[11] - Non-GAAP net earnings per diluted share were $1.77[10], at the high end of guidance[11] - Adjusted EBITDA was $240 million[10] - Non-GAAP gross margin was 46.6%[10] Segment Performance - Semiconductor revenue was $432 million[12], a 17% year-over-year increase or 16% excluding FX impacts[12] - Electronics & Packaging revenue was $266 million[19], a 16% year-over-year increase excluding FX and Palladium impacts, or 14% year-over-year increase[19] - Specialty Industrial revenue was $275 million[26], a 5% year-over-year decrease excluding FX and Palladium impacts, or 6% year-over-year decrease[26] Q3 2025 Outlook - Revenue is projected to be $960 million, with a variance of plus or minus $40 million[40] - Semiconductor revenue is expected to be $405 million, with a variance of plus or minus $15 million[16, 43] - Electronics & Packaging revenue is expected to be $285 million, with a variance of plus or minus $10 million[23, 43] - Specialty Industrial revenue is expected to be $270 million, with a variance of plus or minus $15 million[30, 43]

August 7, 2025 Introduction Executive Officer Kirk Perry Amit Banati Sofya Tsinis Interim Chief Chief Financial Officer 2 Second Quarter 2025 Vice President of Investor Relations Cautionary note on forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about management's expectations of Kenvue's future operating and financial performance, product development, market positi ...

Financial Performance - Avadel Pharmaceuticals generated $68.1 million in net revenue in Q2 2025, a 64% year-over-year increase[13] - The company raised FY25 revenue guidance to $265 - $275 million[13] - Avadel achieved cash-flow positive status in Q2 2025[13] - Cash, cash equivalents, and marketable securities totaled $81.5 million as of June 30, 2025[13] - GAAP Operating Income for Q2 2025 was $8.9 million, compared to a loss of $12.7 million in Q2 2024[22] - Non-GAAP Operating Income for Q2 2025 was $15.0 million, compared to a loss of $1.2 million in Q2 2024[24] LUMRYZ and Pipeline Development - Approximately 3,100 patients are currently on LUMRYZ therapy, a 63% increase compared to June 30, 2024[9, 13] - The REVITALYZ Phase 3 trial of LUMRYZ in Idiopathic Hypersomnia (IH) is on track to complete enrollment during 4Q25, with data expected in 1H26[13] - LUMRYZ received Orphan Drug Designation for Idiopathic Hypersomnia (IH)[13] - Approximately 11% of the 42,000 US patients diagnosed with IH are treated with the only FDA approved oxybate treatment[18]